Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

December 2, 2024

Study Completion Date

February 2, 2025

Conditions
Liposarcoma, MyxoidLiposarcoma, DedifferentiatedLiposarcoma, Round Cell
Interventions
DRUG

Trabectedin

Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.

DRUG

Pioglitazone Oral Product

Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale Tumori, Milan

All Listed Sponsors
collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

collaborator

Humanitas Hospital, Italy

OTHER

lead

Mario Negri Institute for Pharmacological Research

OTHER